Brief: Checkpoint Therapeutics Announces FDA Approval Of Unloxcyt (Cosibelimab-Ipdl)
13/12/2024 23:17
Dec 13 (Reuters) - Checkpoint Therapeutics Inc CKPT.O :
* CHECKPOINT THERAPEUTICS ANNOUNCES FDA APPROVAL OF
UNLOXCYT™ (COSIBELIMAB-IPDL)
Source text: urn:newsml:reuters.com:*:nGNX3Mnqk6
Further company coverage: CKPT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fortress Biotech
See all newsFortress Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Fortress Biotech Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Fortress Biotech And Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
Fortress Biotech Q1 net income jumps on PRV sale
Brief: Journey Medical Corporation Secures Contract With Third Major Gpo For Emrosi